Esperion Therapeutics (ESPR) Misses Q1 EPS by 8c

Esperion Therapeutics (NASDAQ: ESPR) reported Q1 EPS of ($0.56), $0.08 worse than the analyst estimate of ($0.48).

For earnings history and earnings-related data on Esperion Therapeutics (ESPR) click here.

You May Also Be Interested In

• Micron offers Taiwan workers up to 68-month bonuses as strike threat looms
• UBS Starts Kalyan Jewellers India Ltd (KALYANKJ:IN) at Buy
• S&P 500 above 8,000 in 2026 now looks ambitious, Citi says